Personalized medicine: State-of-the-art and prospects

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 12, 2012, Pages 4-12

  Dedov, I I ^a   Tyul'Pakov, A N ^a   Chekhonin, V P ^b   Baklaushev, V P ^b   Archakov, A I ^c   Moshkovskii, S A ^c  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^c INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Genomics; Metabolomics; Personalized mediane; Proteomics; Therapeutic drug monitoring

Indexed keywords

EID: 84875801458     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: 10.15690/vramn.v67i12.474     Document Type: Review

References (93)

1. DeGoma E.M., Rivera G., Lilly S.M., et al. Personalized vascular medicine: individualizing drug therapy. Vascular Med 2011; 16(5):391-404.
2. Hamburg MA., Collins ES. The path to personalized medicine. NEngl J Med 2010; 363(4): 301-304.
3. Chan I.S., Ginsburg G.S. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet 2011; 12:217-44.
4. Jain K.K. From molecular diagnostics to personalized medicine. Exp Rev MoI Diagn 2002; 2(4):299-301. (Pubitemid 34764479)
5. Jain K.K. Nanobiotechnology and personalized medicine. Prog Mol Biol Transi Sci 2011; 104:325-54.
6. de Miranda D.M., Mamede M., de Souza B.R., et al. Molecular medicine: a path towards a personalized medicine. Rev Bras Psiquiatr 2012; 34(1): 82-91.
7. Whitcomb D.C. Going MAD: development of a «matrix academic division» to facilitate translating research to personalized medicine. Acad Med 2011; 86(11):1353-1359.
8. Scudellari M. Genomics contest underscores challenges of personalized medicine. Nat Med 2012; 18(3):326.
9. Hoggatt J. Personalized medicine trends in molecular diagnostics: exponential growth expected in the next ten years. MoI Diagn Ther 2011; 15(1):53-5.
10. Hodgson D.R., Wellings R., Harbron C. Practical perspectives of personalized healthcare in oncology. N Biotechnol 2012; Mar 15. (Epub ahead of print).
11. Thomson A. Why do therapeutic drug monitoring. The Pharm. Journal 2004; 273:153-155. (Pubitemid 39162830)
12. Baltimore D. Our genome unveiled. Nature 2001; 409(6822): 814-816. (Pubitemid 32165326)
13. Lander E.S., Linton L.M., Büren B., et al. Initial sequencing and analysis of the human genome. Nature 2001; 409(6822):860-921. (Pubitemid 32165345)
14. Peltonen L., McKusick VA. Dissecting human disease in the postgenomic era. Science 2001; 291(5507):1224-29. (Pubitemid 32173078)
15. Kaiser J. The genome project: what will it do as a teenager? Science 2011; 331(6018):660.
16. Johnson AD., O'Donnell CJ. An open access database of genomewide association results. BMC Med Genet 2009; 10:6.
17. Thompson AJ., Muir AJ., Sulkowski M.S., et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologie response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139(1): 120-29.
18. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statininduced myopathy: a genomewide study. N. Engl. J. Med 2008; 359(8):789-99.
19. Neben D.W., Zhang G. Personalize medicine: temper expectations. Science 2012, 337(6097):910.
20. Archey W.B., McEachern K.A., Robson M., et al. Increased CpG methylation of the estrogen receptor gene in B RCAl-linked estrogen receptor-negative breast cancers. Oncogene 2002; 21(46): 7034-7041. (Pubitemid 35252977)
21. Devaskar S.U., Thamotharan M. Metabolic programming in the pathogenesis of insulin resistance. Rev Endocr Metab Disord 2007; 8(2):105-113. (Pubitemid 47434650)
22. Corwin EJ. The concept of epigenetics and its role in the development of cardiovascular disease: commentary on «New and emerging theories of cardiovascular disease». Biol Res Nurs 2004; 6(1): 11-16, 21-23.
23. Futreal P.A., Coin L., Marshall M., et al. A census of human cancer genes. Nat Rev Cancer 2004; 4(3):177-183. (Pubitemid 38337497)
24. Garber K. Human Cancer Genome Project moving forward despite some doubts in community. / Nat Cancer Inst 2005; 97(18): 1322-24. (Pubitemid 41487794)
25. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286(5439):531-37.
26. Newell K.A., Asare A., Kirk A.D., et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Investig 2010; 120(6): 1836-47.
27. Rosenberg S., Elashoff M.R., Beineke P., et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 2010; 153(7):425-34.
28. Klein T.E., Altman R.B., Eriksson N., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl J Med 2009; 360(8):753-64.
29. Moyer V.A., U.S. Preventive Services Task Force. Screening for prostate cancer U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157(2):120-134.
30. Van't Veer L.J.,Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415(6871):530-36.
31. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2):281-297.
32. Jopling CL., Yi M., Lancaster A.M., et al. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 2005; 309(5740):1577-81. (Pubitemid 41266486)
33. Jain K.K. Role of pharmacoproteomics in the development of personalized medicine. Pharmacogenomics 2004; 5(3):331-6. (Pubitemid 38499971)
34. Archakov A., Aseev A., Bykov V, et al. Gene-centric view on the human proteome project: the example of the Russian roadmap for chromosome 18. Proteomics 2011; 11(10):1853-1856.
35. Rauser S., Deininger S.O., Suckau D., et al. Approaching MALDI molecular imaging for clinical proteomic research: current state and fields of application. Expert Review of Proteomics 2010; 7(6): 927-941.
36. Reddy RJ., Jain R., Paik Y.K., et al. Personalized medicine in the age of pharmacoproteomics: a close up on India and need for social science engagement for responsible innovation in postproteomic biology. Curr Pharmacogenomics Person Med 2011; 9(l):67-75.
37. Karpova MA., Moshkovskii S.A., Toropygin I.Y., Archakov A.I. Cancer-specific MALDI-TOF profiles of blood serum and plasma: biological meaning and perspectives.J. Proteomics 2010; 73(3): 537-551.
38. Hyung S.W., Lee M.Y., Yu J.H., et al A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers. Mol Cell Proteomics 2011; 10(10): M111.011023.
39. Sakamoto J.H., van de ven A.L., Godin B., et al. Enabling individualized therapy through nanotechnology. Pharmacol Res 2010; 62(2):57-89.
40. Leth-Larsen R., Lund R.R., Ditzel H.J. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. MoI Cell Proteomics 2010; 9(7):1369-1382.
41. Chumbalkar VC, Subhashini C, Dhople V.M., et al. Differential protein expression in human gliomas and molecular insights. Proteomics 2005; 5(4):1167-1177. (Pubitemid 40469044)
42. Young J., Stone W.L. Pediatric proteomics: an introduction. Front Biosci 2012;4:1078-1087.
43. Rajaraman P., Melin B.S., Wang Z., et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012 [Epub ahead of print]
44. Archakov A.I., Ivanov YD., Lisitsa A. V, Zgoda VG. AFM fishing nanotechnology is the way to reverse the Avogadro number in proteomics. Proteomics. 2007. 7(l):4-9. (Pubitemid 46173710)
45. Zgoda VG., Kopylov A. T, Lisitsa A.V. Combined use of irreversible binding and multiple reaction monitoring technology for low- and ultra-low copy-number protein detection and quantitation. J Proteomics. In press.
46. Lapuk A.V, Wu C, Wyatt A.W, et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol. 2012; 227(3):286-297.
47. Su Z.D., Sun L., Yu D.X., et al. Quantitative detection of single amino acid polymorphisms by targeted proteomics. J MoI Cell Biol 2011;3(5):309-115.
48. Omenn G.S., Yocum A.K., Menon R. Alternative splice variants, a new class of protein cancer biomarker candidates: findings in pancreatic cancer and breast cancer with systems biology implications. Dis Markers. 2010; 28(4):241-251.
49. Serkova N.J., Brown M.S. Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers. Bioanalysis 2012; 4(3):321-341.
50. Sreekumar A., Poisson L.M., Rajendiran T.M., et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009. 457(7231):910-914.
51. Lokhov P.G., Dashtiev M.I., Moshkovskii S.A, Archakov A.I. Metabolite profiling of blood plasma of patients with prostate cancer. Metabolomics 2009; 6(1): 156-163.
52. Marko-Varga G. BioBanking - The Holy Grail of novel drug and diagnostic developments? J Clin Bioinforma. 2011; 1(1):14.
53. Botti G., Franco R., Cantile M., et al. Tumor biobanks in translational medicine. J Transi Med. 2012; 10(1): 204.
54. Chen R., Mias G.I., Li-Pook-Than J., et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148(6):1293-1307.
55. Samot J., Moon S., Shao L., et al. Blood banking in living droplets. PLoS One. 2011; 6(3): e 17530.
56. Patel A. Tissue banking for research-bench to bedside and backmyth, reality or fast fading reality at the dawn of a personalised healthcare era. Cell Tissue Bank. 2011; 12(1): 19-21.
57. Diilner J., Andersson K. Biobanks collected for routine healthcare purposes: build-up and use for epidemiologic research. Methods Mol Biol. 2011;675:113-25.
58. Gibson W.M. Can personalized medicine survive? Can Fam Physician 1971; 17(8):29-88.
59. Arnold R.M., Forrow L. Rewarding medicine: good doctors and good behavior. Ann Intern Med 1990; 113(10):794-798. (Pubitemid 20369670)
60. Jain K.K. Personalized medicine. Waltham: Decision Resources Inc, 1998.
61. Marshall W.J., Bangert S.K. Clinical Chemistry, 6th Edition. Edinburgh, London: Mosby Elsevier, 2008.
62. Patsalos P.N., Berry D.J., Bourgeois B.F., et al. Antiepileptic drugs - best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-1276. (Pubitemid 351991390)
63. Schwenger E., Dumontet J., Ensom M.H. Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia? Clin Pharmacokinet 2011; 50(7):415-428.
64. D'Souza R., Rajji T.K., Mulsant B.H., Pollock B.G. Use of lithium in the treatment of bipolar disorder in late-life. Curr Psychiatry Rep 2011; 13(6):488-492.
65. Touw D.J., Westerman E.M., Sprij A.J. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009; 48(2):71-88.
66. Dartois V, Barry CE. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensivelydrug resistant (XDR) tuberculosis. Curr Clin Pharmacol 2010; 5(2):96-114.
67. Pieri M., Miraglia N., Polichetti G., et al. Analytical and pharmacological aspects of therapeutic drug monitoring of mTOR inhibitors. Curr Drug Metab 2011; 12(3):253-267.
68. Vtklenga J.M., Hoppensteadt D.A. Monitoring the new antithrombotic drugs. Semin Thromb Hemost 2004; 30(6):683-695. (Pubitemid 40041604)
69. Wiseman J.M., Evans CA., Bowen CL., Kennedy J.H. Direct analysis of dried blood spots utilizing desorption electrospray ionization (DESI) mass spectrometry. Analyst 2010; 135(4):720-725.
70. Pene F., Courtine E., Cariou A., Mira J.P. Toward theranostics. Crit Care Med. 2009. 37:S50-S58.
71. Search Collaborative Group, Link E., Parish S., et al. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl J Med 2008; 359(8):789-799.
72. Ford L.T., Berg J.D. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol. 2010; 63(4):288-95.
73. Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest. 2010;40(10):950-9.
74. Bibeau E, Louvet C, Afchain P., et al. Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment. Bull Cancer. 2012 [Epub ahead of print].
75. Jennings B., Hadfield J.E., Vtorsley S.D., et al. A differential PCR assay for the detection of c-erbB 2 amplification used in a prospective study of breast cancer. Molecular Pathology. 1997. 50(5): 254-256. (Pubitemid 27475775)
76. Li H.W., Sykes M. Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol 2012; 12(6):403-416.
77. Herbert K.E., Levesque J.P., Mills A.K., et al. How we mobilize haemopoietic stem cells. Intern Med J 2011; 41(8):588-594.
78. Wlodarski K. H. Haematopoietic and osteogenic bone marrow stem cells. Ortop Traumatol Rehabil 2011; 13(5):439-447.
79. Greco S.J., Rameshwar P. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Ther Dellv 2012; 3(8):9971004.
80. Ming G.L., Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011; 70(4):687-702.
81. Roh J.K., Jung K.H., Chu K. Adult stem cell transplantation in stroke: its limitations and prospects. Curr Stem Cell Res Ther. 2008; 3(3): 185-196.
82. Prasad K., Mohanty S., Bhatia R., et al. Autologous intravenous bone marrow mononuclear cell therapy for patients with subacute ischaemic stroke: A pilot study. Indian J Med Res 2012; 136(2):221-228.
83. Pal S.N., Kofidis T. New cell therapies in cardiology. Expert Rev Cardiovasc Ther2012; 10(8):1023-1037.
84. Sng J., Lufkin T. Emerging stem cell therapies: treatment, safety, and biology. Stem Cells International; 2012 (Epub).
85. Fülle S., Centurione L., Mancinelli R., et al. Stem cell ageing and apoptosis. Curr Pharm 2012; 18(13): 1694-1717.
86. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell2006;126(4):663- 676.
87. Robinton D.A., Daley G.Q. The promise of induced pluripotent stem cells in research and therapy. Nature 2012; 481(7381): 295-305.
88. Zineh I., Huang S.M. Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med 2011; 5(6):705-713.
89. Nishiyama M. Personalized medicine and molecular targets of drugs. Nihon Rinsho 2010; 68(10):1917-1922.
90. Mirnezami R., Nicholson J., Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366(6):489-491.
91. Swenerton K.D., Santos J.L., Gilks C.B., et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol 2011; 22(2):341-347.
92. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; doi:10.1038/naturell412. Epub ahead of print.
93. Menon R., Omenn G.S. Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res. 2010; 70(9):3440-3449.